{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:31:53Z","timestamp":1793788313174,"version":"4.6.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alzheimer\u2019s disease (AD) is traditionally defined by the presence of two types of protein aggregates in the brain: amyloid plaques comprised of the protein amyloid-\u03b2 (A\u03b2) and neurofibrillary tangles containing the protein tau. However, a large proportion (up to 57%) of AD patients also have TDP-43 aggregates present as an additional comorbid pathology. The presence of TDP-43 aggregates in AD correlates with hippocampal sclerosis, worse brain atrophy, more severe cognitive impairment, and more rapid cognitive decline. In patients with mixed A\u03b2, tau, and TDP-43 pathology, TDP-43 may interact with neurodegenerative processes in AD, worsening outcomes. While considerable progress has been made to characterize TDP-43 pathology in AD and late-onset dementia, there remains a critical need for mechanistic studies to understand underlying disease biology and develop therapeutic interventions. This perspectives article reviews the current understanding of these processes from autopsy cohort studies and model organism-based research, and proposes targeting neurotoxic synergies between tau and TDP-43 as a new therapeutic strategy for AD with comorbid TDP-43 pathology.<\/jats:p>","DOI":"10.1007\/s11357-021-00407-0","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T07:02:47Z","timestamp":1624950167000},"page":"1627-1634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"43","author":[{"given":"Caitlin S.","family":"Latimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1250-3871","authenticated-orcid":false,"given":"Nicole F.","family":"Liachko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"issue":"1","key":"407_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 2012;123(1):1\u201311.","journal-title":"Acta Neuropathol"},{"key":"407_CR2","doi-asserted-by":"crossref","unstructured":"Behl T, et al. Exploring the potential of therapeutic agents targeted towards mitigating the events associated with amyloid-beta cascade in Alzheimer's disease. Int J Mol Sci. 2020;21(20).","DOI":"10.3390\/ijms21207443"},{"issue":"2","key":"407_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bmcl.2018.11.034","volume":"29","author":"PV Fish","year":"2019","unstructured":"Fish PV, et al. New approaches for the treatment of Alzheimer\u2019s disease. Bioorg Med Chem Lett. 2019;29(2):125\u201333.","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"407_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362\u201381.","journal-title":"J Neuropathol Exp Neurol"},{"key":"407_CR5","doi-asserted-by":"crossref","unstructured":"Pluta R and Ulamek-Koziol M. Tau protein-targeted therapies in Alzheimer's disease: current state and future perspectives, in Alzheimer's Disease: Drug Discovery, X. Huang, Editor. 2020. Brisbane (AU).","DOI":"10.36255\/exonpublications.alzheimersdisease.2020.ch4"},{"issue":"1","key":"407_CR6","doi-asserted-by":"crossref","first-page":"e12070","DOI":"10.1002\/trc2.12070","volume":"6","author":"ER Hascup","year":"2020","unstructured":"Hascup ER, Hascup KN. Toward refining Alzheimer\u2019s disease into overlapping subgroups. Alzheimers Dement (NY). 2020;6(1):e12070.","journal-title":"Alzheimers Dement (NY)"},{"issue":"1","key":"407_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ng1934","volume":"39","author":"L Bertram","year":"2007","unstructured":"Bertram L, et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39(1):17\u201323.","journal-title":"Nat Genet"},{"issue":"5123","key":"407_CR8","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261(5123):921\u20133.","journal-title":"Science"},{"key":"407_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.neurobiolaging.2018.06.012","volume":"70","author":"D Chan","year":"2018","unstructured":"Chan D, et al. Lifestyle activities in mid-life contribute to cognitive reserve in late-life, independent of education, occupation, and late-life activities. Neurobiol Aging. 2018;70:180\u20133.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"407_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/geronb\/gbw124","volume":"72","author":"AJ Gow","year":"2017","unstructured":"Gow AJ, Pattie A, Deary IJ. lifecourse activity participation from early, mid, and later adulthood as determinants of cognitive aging: the lothian birth cohort 1921. J Gerontol B Psychol Sci Soc Sci. 2017;72(1):25\u201337.","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"issue":"5","key":"407_CR11","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1080\/13607860410001725072","volume":"8","author":"M Kliegel","year":"2004","unstructured":"Kliegel M, Zimprich D, Rott C. Life-long intellectual activities mediate the predictive effect of early education on cognitive impairment in centenarians: a retrospective study. Aging Ment Health. 2004;8(5):430\u20137.","journal-title":"Aging Ment Health"},{"issue":"1","key":"407_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00401-013-1226-2","volume":"127","author":"DA Bennett","year":"2014","unstructured":"Bennett DA, et al. Cognitive and social lifestyle: links with neuropathology and cognition in late life. Acta Neuropathol. 2014;127(1):137\u201350.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"407_CR13","doi-asserted-by":"publisher","first-page":"718","DOI":"10.2174\/156720512801322555","volume":"9","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, et al. Adult Changes in Thought study: dementia is an individually varying convergent syndrome with prevalent clinically silent diseases that may be modified by some commonly used therapeutics. Curr Alzheimer Res. 2012;9(6):718\u201323.","journal-title":"Curr Alzheimer Res"},{"issue":"11","key":"407_CR14","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1212\/WNL.0000000000002480","volume":"86","author":"LR White","year":"2016","unstructured":"White LR, et al. Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia aging studies. Neurology. 2016;86(11):1000\u20138.","journal-title":"Neurology"},{"issue":"3","key":"407_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1037\/neu0000159","volume":"29","author":"L Yu","year":"2015","unstructured":"Yu L, et al. Residual decline in cognition after adjustment for common neuropathologic conditions. Neuropsychology. 2015;29(3):335\u201343.","journal-title":"Neuropsychology"},{"issue":"Suppl 1","key":"407_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/jnc.13625","volume":"138","author":"A Ratti","year":"2016","unstructured":"Ratti A, Buratti E. Physiological functions and pathobiology of TDP-43 and FUS\/TLS proteins. J Neurochem. 2016;138(Suppl 1):95\u2013111.","journal-title":"J Neurochem"},{"issue":"5796","key":"407_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130\u20133.","journal-title":"Science"},{"issue":"3","key":"407_CR18","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bbrc.2006.10.093","volume":"351","author":"T Arai","year":"2006","unstructured":"Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602\u201311.","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"407_CR19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrneurol.2012.117","volume":"8","author":"R Rademakers","year":"2012","unstructured":"Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol. 2012;8(8):423\u201334.","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"407_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S1474-4422(08)70071-1","volume":"7","author":"VM Van Deerlin","year":"2008","unstructured":"Van Deerlin VM, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol. 2008;7(5):409\u201316.","journal-title":"Lancet Neurol"},{"issue":"2","key":"407_CR21","first-page":"147","volume":"4","author":"AC Wilson","year":"2011","unstructured":"Wilson AC, et al. TDP-43 in aging and Alzheimer\u2019s disease - a review. Int J Clin Exp Pathol. 2011;4(2):147\u201355.","journal-title":"Int J Clin Exp Pathol"},{"issue":"6","key":"407_CR22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00401-011-0879-y","volume":"122","author":"YS Davidson","year":"2011","unstructured":"Davidson YS, et al. TDP-43 pathological changes in early onset familial and sporadic Alzheimer\u2019s disease, late onset Alzheimer\u2019s disease and Down\u2019s syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol. 2011;122(6):703\u201313.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"407_CR23","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00401-014-1269-z","volume":"127","author":"KA Josephs","year":"2014","unstructured":"Josephs KA, et al. TDP-43 is a key player in the clinical features associated with Alzheimer\u2019s disease. Acta Neuropathol. 2014;127(6):811\u201324.","journal-title":"Acta Neuropathol"},{"key":"407_CR24","doi-asserted-by":"crossref","unstructured":"Nelson PT, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019.","DOI":"10.1093\/brain\/awz186"},{"issue":"6","key":"407_CR25","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/jnen\/nlw033","volume":"75","author":"PT Nelson","year":"2016","unstructured":"Nelson PT, et al. \"New Old Pathologies\": AD, PART, and cerebral age-related TDP-43 With sclerosis (CARTS). J Neuropathol Exp Neurol. 2016;75(6):482\u201398.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"11","key":"407_CR26","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1093\/brain\/aww224","volume":"139","author":"BD James","year":"2016","unstructured":"James BD, et al. TDP-43 stage, mixed pathologies, and clinical Alzheimer\u2019s-type dementia. Brain. 2016;139(11):2983\u201393.","journal-title":"Brain"},{"issue":"9","key":"407_CR27","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S1474-4422(18)30251-5","volume":"17","author":"HS Yang","year":"2018","unstructured":"Yang HS, et al. Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE epsilon4 haplotype status: a community-based cohort study. Lancet Neurol. 2018;17(9):773\u201381.","journal-title":"Lancet Neurol"},{"issue":"6","key":"407_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1212\/WNL.0000000000001831","volume":"85","author":"CH Kawas","year":"2015","unstructured":"Kawas CH, et al. Multiple pathologies are common and related to dementia in the oldest-old: the 90+ study. Neurology. 2015;85(6):535\u201342.","journal-title":"Neurology"},{"issue":"3","key":"407_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00401-018-1872-5","volume":"136","author":"JL Robinson","year":"2018","unstructured":"Robinson JL, et al. Non-Alzheimer\u2019s contributions to dementia and cognitive resilience in the 90+ study. Acta Neuropathol. 2018;136(3):377\u201388.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"407_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00401-013-1110-0","volume":"126","author":"SJ Arnold","year":"2013","unstructured":"Arnold SJ, Dugger BN, Beach TG. TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies. Acta Neuropathol. 2013;126(1):51\u20137.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"407_CR31","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1212\/WNL.0000000000003610","volume":"88","author":"S Nag","year":"2017","unstructured":"Nag S, et al. TDP-43 pathology and memory impairment in elders without pathologic diagnoses of AD or FTLD. Neurology. 2017;88(7):653\u201360.","journal-title":"Neurology"},{"issue":"11","key":"407_CR32","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1474-4422(17)30284-3","volume":"16","author":"KA Josephs","year":"2017","unstructured":"Josephs KA, et al. Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer\u2019s disease: a longitudinal retrospective study. Lancet Neurol. 2017;16(11):917\u201324.","journal-title":"Lancet Neurol"},{"issue":"1","key":"407_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40478-019-0743-1","volume":"7","author":"CS Latimer","year":"2019","unstructured":"Latimer CS, et al. Resistance and resilience to Alzheimer\u2019s disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort. Acta Neuropathol Commun. 2019;7(1):91.","journal-title":"Acta Neuropathol Commun"},{"issue":"8","key":"407_CR34","doi-asserted-by":"publisher","first-page":"844","DOI":"10.2174\/15672050113109990157","volume":"10","author":"S Negash","year":"2013","unstructured":"Negash S, et al. Resilient brain aging: characterization of discordance between Alzheimer\u2019s disease pathology and cognition. Curr Alzheimer Res. 2013;10(8):844\u201351.","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"407_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13195-019-0479-y","volume":"11","author":"TJ Montine","year":"2019","unstructured":"Montine TJ, et al. Concepts for brain aging: resistance, resilience, reserve, and compensation. Alzheimers Res Ther. 2019;11(1):22.","journal-title":"Alzheimers Res Ther"},{"key":"407_CR36","doi-asserted-by":"crossref","unstructured":"Josephs KA, et al. Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology. 2008.","DOI":"10.1212\/01.wnl.0000304041.09418.b1"},{"issue":"11","key":"407_CR37","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1001\/jamaneurol.2013.3961","volume":"70","author":"RS Wilson","year":"2013","unstructured":"Wilson RS, et al. TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol. 2013;70(11):1418\u201324.","journal-title":"JAMA Neurol"},{"issue":"1","key":"407_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40478-018-0531-3","volume":"6","author":"S Nag","year":"2018","unstructured":"Nag S, et al. TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer\u2019s disease. Acta Neuropathol Commun. 2018;6(1):33.","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"407_CR39","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00401-016-1537-1","volume":"131","author":"KA Josephs","year":"2016","unstructured":"Josephs KA, et al. Updated TDP-43 in Alzheimer\u2019s disease staging scheme. Acta Neuropathol. 2016;131(4):571\u201385.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"407_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/ana.25246","volume":"84","author":"MC Power","year":"2018","unstructured":"Power MC, et al. Combined neuropathological pathways account for age-related risk of dementia. Ann Neurol. 2018;84(1):10\u201322.","journal-title":"Ann Neurol"},{"issue":"9","key":"407_CR41","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1021\/jacs.0c12729","volume":"143","author":"V Laos","year":"2021","unstructured":"Laos V, et al. Catalytic Cross talk between key peptide fragments that couple Alzheimer\u2019s disease with amyotrophic lateral sclerosis. J Am Chem Soc. 2021;143(9):3494\u2013502.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"407_CR42","doi-asserted-by":"publisher","first-page":"5950","DOI":"10.1038\/s41467-020-19786-7","volume":"11","author":"YH Shih","year":"2020","unstructured":"Shih YH, et al. TDP-43 interacts with amyloid-beta, inhibits fibrillization, and worsens pathology in a model of Alzheimer\u2019s disease. Nat Commun. 2020;11(1):5950.","journal-title":"Nat Commun"},{"key":"407_CR43","doi-asserted-by":"crossref","unstructured":"Hicks DA, et al. The cellular expression and proteolytic processing of the amyloid precursor protein is independent of TDP-43. Biosci Rep. 2020;40(4).","DOI":"10.1042\/BSR20200435"},{"issue":"2","key":"407_CR44","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3233\/JAD-201032","volume":"79","author":"SJ Teipel","year":"2021","unstructured":"Teipel SJ, et al. Association of TDP-43 Pathology with global and regional 18F-florbetapir PET signal in the Alzheimer\u2019s disease Spectrum. J Alzheimers Dis. 2021;79(2):663\u201370.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"407_CR45","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-021-02295-2","volume":"141","author":"SO Tome","year":"2021","unstructured":"Tome SO, et al. TDP-43 interacts with pathological tau protein in Alzheimer\u2019s disease. Acta Neuropathol. 2021;141(5):795\u20139.","journal-title":"Acta Neuropathol"},{"key":"407_CR46","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.brainres.2007.09.048","volume":"1184","author":"S Higashi","year":"2007","unstructured":"Higashi S, et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer\u2019s disease and dementia with Lewy bodies. Brain Res. 2007;1184:284\u201394.","journal-title":"Brain Res"},{"key":"407_CR47","doi-asserted-by":"crossref","unstructured":"Kadokura A, et al. Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology. Neuropathology. 2009.","DOI":"10.1111\/j.1440-1789.2009.01017.x"},{"issue":"2","key":"407_CR48","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/bpa.12505","volume":"28","author":"VD Smith","year":"2018","unstructured":"Smith VD, et al. Overlapping but distinct TDP-43 and tau pathologic patterns in aged hippocampi. Brain Pathol. 2018;28(2):264\u201373.","journal-title":"Brain Pathol"},{"issue":"2","key":"407_CR49","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00401-016-1662-x","volume":"133","author":"E Drummond","year":"2017","unstructured":"Drummond E, Wisniewski T. Alzheimer\u2019s disease: experimental models and reality. Acta Neuropathol. 2017;133(2):155\u201375.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"407_CR50","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1242\/dmm.029058","volume":"10","author":"P Van Damme","year":"2017","unstructured":"Van Damme P, Robberecht W, Van Den Bosch L. Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis Model Mech. 2017;10(5):537\u201349.","journal-title":"Dis Model Mech"},{"issue":"25","key":"407_CR51","doi-asserted-by":"publisher","first-page":"10600","DOI":"10.1074\/jbc.M117.783498","volume":"292","author":"J Gu","year":"2017","unstructured":"Gu J, et al. Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: implications for the pathogenesis of tauopathies. J Biol Chem. 2017;292(25):10600\u201312.","journal-title":"J Biol Chem"},{"key":"407_CR52","doi-asserted-by":"crossref","unstructured":"Montalbano M, et al. TDP-43 and Tau oligomers in Alzheimer's disease, Amyotrophic lateral sclerosis, and frontotemporal dementia. Neurobiol Dis. 2020;146:105130.","DOI":"10.1016\/j.nbd.2020.105130"},{"issue":"1","key":"407_CR53","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s40478-019-0816-1","volume":"7","author":"AJ Moszczynski","year":"2019","unstructured":"Moszczynski AJ, et al. Synergistic toxicity in an in vivo model of neurodegeneration through the co-expression of human TDP-43(M337V) and tau(T175D) protein. Acta Neuropathol Commun. 2019;7(1):170.","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"407_CR54","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"key":"407_CR55","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fnagi.2019.00204","volume":"11","author":"P Barbier","year":"2019","unstructured":"Barbier P, et al. Role of tau as a microtubule-associated protein: structural and functional aspects. Front Aging Neurosci. 2019;11:204.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"407_CR56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/biom6010009","volume":"6","author":"M BukarMaina","year":"2016","unstructured":"BukarMaina M, Al-Hilaly YK, Serpell LC. Nuclear Tau and its potential role in Alzheimer\u2019s disease. Biomolecules. 2016;6(1):9.","journal-title":"Biomolecules"},{"issue":"10","key":"407_CR57","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.neuron.2021.03.026","volume":"109","author":"E Lester","year":"2021","unstructured":"Lester E, et al. Tau aggregates are RNA-protein assemblies that mislocalize multiple nuclear speckle components. Neuron. 2021;109(10):1675-1691 e9.","journal-title":"Neuron"},{"key":"407_CR58","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3389\/fnmol.2019.00301","volume":"12","author":"L Francois-Moutal","year":"2019","unstructured":"Francois-Moutal L, et al. Structural insights Into TDP-43 and effects of post-translational modifications. Front Mol Neurosci. 2019;12:301.","journal-title":"Front Mol Neurosci"},{"issue":"3","key":"407_CR59","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jsb.2009.06.006","volume":"167","author":"I Casafont","year":"2009","unstructured":"Casafont I, et al. TDP-43 localizes in mRNA transcription and processing sites in mammalian neurons. J Struct Biol. 2009;167(3):235\u201341.","journal-title":"J Struct Biol"},{"issue":"13","key":"407_CR60","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1016\/j.celrep.2019.11.093","volume":"29","author":"DJ Apicco","year":"2019","unstructured":"Apicco DJ, et al. Dysregulation of RNA splicing in tauopathies. Cell Rep. 2019;29(13):4377-4388 e4.","journal-title":"Cell Rep"},{"issue":"2","key":"407_CR61","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.celrep.2019.08.104","volume":"29","author":"YC Hsieh","year":"2019","unstructured":"Hsieh YC, et al. Tau-mediated disruption of the spliceosome triggers cryptic RNA splicing and neurodegeneration in Alzheimer\u2019s disease. Cell Rep. 2019;29(2):301-316 e10.","journal-title":"Cell Rep"},{"key":"407_CR62","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.3389\/fneur.2020.01056","volume":"11","author":"L Diez","year":"2020","unstructured":"Diez L, Wegmann S. Nuclear Transport deficits in tau-related neurodegenerative diseases. Front Neurol. 2020;11:1056.","journal-title":"Front Neurol"},{"key":"407_CR63","doi-asserted-by":"crossref","unstructured":"Fallini C, et al. Traffic jam at the nuclear pore: all roads lead to nucleocytoplasmic transport defects in ALS\/FTD. Neurobiol Dis. 2020;140:104835.","DOI":"10.1016\/j.nbd.2020.104835"},{"key":"407_CR64","doi-asserted-by":"crossref","unstructured":"Eck RJ, Kraemer BC, and Liachko NF. Regulation of TDP-43 phosphorylation in aging and disease. Geroscience. 2021.","DOI":"10.1007\/s11357-021-00383-5"},{"key":"407_CR65","doi-asserted-by":"crossref","unstructured":"Deshimaru M, et al. DCTN1 Binds to TDP-43 and regulates TDP-43 Aggregation. Int J Mol Sci. 2021;22(8).","DOI":"10.3390\/ijms22083985"},{"issue":"3","key":"407_CR66","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00401-013-1211-9","volume":"127","author":"KA Josephs","year":"2014","unstructured":"Josephs KA, et al. Staging TDP-43 pathology in Alzheimer\u2019s disease. Acta Neuropathol. 2014;127(3):441\u201350.","journal-title":"Acta Neuropathol"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-021-00407-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-021-00407-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-021-00407-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T11:57:16Z","timestamp":1699185436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-021-00407-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["407"],"URL":"https:\/\/doi.org\/10.1007\/s11357-021-00407-0","relation":{},"ISSN":["2509-2715","2509-2723"],"issn-type":[{"value":"2509-2715","type":"print"},{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]},"assertion":[{"value":"4 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}